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Bypass versus Angioplasty in Severe Ischaemia of
the Leg (BASIL) trial in perspective
Andrew W. Bradbury, BSc, MD, MBA, FRCSEd, on behalf of the BASIL trial Investigators and
Participants, Birmingham, United KingdomIn the United Kingdom (UK) through the 1990s,
there had developed an increasing trend in certain high-
profile vascular centers toward treating patients with limb-
threatening lower limb ischemia by means of (subintimal)
balloon angioplasty (BAP) rather than traditional bypass
surgery (BSX) in an attempt to reduce the morbidity,
mortality, and costs associated with intervention. Although
uncontrolled observational series suggested that BAP could
be associated with acceptable limb salvage rates, at least in
the short-term, previous studies comparing BSX and BAP
had all had serious methodologic limitations.1,2 As a result,
vascular surgeons and some interventional radiologists
feared that the non-evidence-based trend toward BAP for
severe limb ischemia (SLI), defined by rest/night pain,
with or without tissue loss, might be associated with sub-
optimal clinical outcomes and might not represent best use
of limited National Health Service (NHS) resources. Many
believed that the time for a randomized controlled trial
(RCT) had come.3
In 1996 the UK National Institute of Health Research
(NIHR) Health Technology Assessment (HTA) program
(http://www.hta.ac.uk/) invited applications for funding to
conduct a RCT to compare the clinical and cost-effectiveness
of BAP vs BSX in SLI. Our group was fortunate enough to
be awarded the commission.
At the time, the Principal Investigator (PI) was working
in Edinburgh and the proposal was to undertake the study
in eight vascular units within Scotland and one in the north
of England. Through a series of meetings with participating
vascular surgeons and interventional radiologists, the trial
protocol was honed, finalized, and agreed to by the HTA.
The trial came to be known as the Bypass versus Angio-
plasty in Severe Ischaemia of the Leg (BASIL) trial.
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doi:10.1016/j.jvs.2010.02.002It is fair to say that there was some skepticismwithin the
UK vascular community that the BASIL trial would ever
enroll enough patients. This was largely because many
believed that surgeons and radiologists, so often en-
trenched in their view of which treatment was better, would
refuse to randomize the patients under their care. There
was also some concern that when offered the choice of
major surgery or angioplasty, a much less invasive proce-
dure, these elderly, infirm patients (or their families) would
refuse randomization even if offered.
It is also worth remembering that although nowadays
we take large pragmatic RCTs for granted—and indeed
expect them to be available to guide practice—that was not
the case 10 to 15 years ago. One senior surgeon apologized
to the PI at the outset of the trial, saying that he could never
put his patients in an RCT because it would mean he would
have to confess that he was not sure how best to treat them.
His view was by no means a solitary one at the time.
And so began a concerted effort to demonstrate to surgi-
cal and interventional colleagues in the various participating
centers, and beyond, that there was, indeed, a wide “gray area
of clinical equipoise.” This public relations campaign involved
presentations at numerous local and national meetings and
the undertaking of a Delphi consensus study among (poten-
tial) participants.4 As we expected, these Delphi studies re-
vealed very substantial disagreements between and among
vascular surgeons and interventional radiologists about the
appropriateness of BSX or BAP for SLI due to infrainguinal
disease.5,6 Participants were, of course, already aware of the
wide variety of views on this issue. However, having seen for
the first time the levels of disagreement quantified, and how
their own views and practice compared with those of their
peers, most participants significantly softened their objections
to the randomization process.
Ethical approval was granted, the trial was registered,
the data monitoring committee and trial steering group
were convened, and the BASIL trial coordinator and re-
search nurses were appointed. The first patient was ran-
domized in August 1999. The PI was soon after appointed
to the Chair of Vascular Surgery in Birmingham, and this
resulted in the trial office and several key staff relocating
from Edinburgh to the Heart of England NHS Trust in the
West Midlands of England during early 2000. This put
back recruitment, and the HTA kindly awarded a 12-
month unfunded extension in recognition of the logistical
problems following on from the relocation.
Although initially difficult, the move to England in
2000 did open up the possibility of greatly increasing the
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ally to 27). In retrospect, it seems likely that the trial would
not have enrolled enough patients had it remained confined
to the centers in Scotland.
The increase in centers and the results of the Delphi
consensus studies greatly increased the rate of randomiza-
tion, and by June 2004, 452 patients had been randomized
and recruitment was stopped because the power calculation
had specified 450 patients.
Overall, about 50% of patients presenting to these UK
vascular centers with SLI underwent immediate or early
revascularization; for a variety of reasons, the other 50%
were treated conservatively in the first instance. Of those
patients being considered for immediate or early revascu-
larization, approximately 30% were found to be eligible for
randomization because the responsible consultant surgeon
and interventional radiologist believed it was appropriate to
offer the patient either BSX or BAP in the first instance; in
the other 70% of patients, the vascular team had a clear
preference for either BSX or BAP.Of these eligible patients,
about 70% entered the trial, a high proportion by RCT
standards and a testament to the enthusiasm of the teams in
the 27 recruiting hospitals.
Trial patients were well matched in terms of baseline
clinical characteristics, angiographic severity, and extent of
disease: 40% patients had diabetes, more than one-third
were still smoking, three-quarters had tissue loss, about
one-third had a highest ankle pressure 50 mm Hg, one-
quarter had bilateral SLI, and most were elderly, with a
significant cardiovascular medical history. Despite this, at
the time of referral to vascular units, one-third of patients
were not receiving an antiplatelet agent and only one-third
was receiving a statin.
In the BSX arm of the trial, approximately 25% of the
bypasses were of prosthetic material, and 90% of the vein
bypasses were constructed using great saphenous vein. The
distal anastomoses were fashioned in approximately equal
numbers at the above knee popliteal, below knee popliteal,
and crural arteries.
In about 70% of patients undergoing BAP, interven-
tional radiologists attempted to treat a single length of
disease (ie, an occlusion or critical stenosis); in the remain-
der, attempts were made to treat several (up to four)
separate diseased lengths. The numbers of transluminal and
subintimal BAP procedures were approximately equal, with
just 10% being reported as mixed. Approximately 80% of
the BAP patients underwent treatment of the superficial
femoral artery either alone (about 40%) or combed with the
popliteal artery (about 40%) and crural arteries (about
20%). Most of the remaining patients underwent treatment
of the popliteal segments either alone, or more usually,
combined with crural arteries; the number of isolated crural
artery BAP was small.
INTERIM (2005) INTENTION-TO-TREAT
ANALYSIS
An intention-to-treat analysis was undertaken during
2004 and 2005, and the trial outcomes were presented forthe first time at the UK Vascular Society meeting in No-
vember 2005. The results were published concurrently in
The Lancet.7 At this stage, the trial showed that there was
no difference in the main clinical outcomes of amputation-
free survival (AFS) and overall survival (OS) between BSX
and BAP out to 2 years but that BSX was about one-third
more expensive in the short-term (first 12 months).
Originally, that was to be the end of the trial, but a post
hoc analysis not specified in the statistical plan showed that
after 2 years, those patients originally randomized to BSX
were less likely subsequently to undergo amputation or to
die. Although these differences were significant, the trial
statistician advised caution, because the analysis was per-
formed after the life tables had been viewed, and the
numbers of end points were relatively small after 2 years.
That said, the investigators and participants thought this
finding was of such potential clinical significance that the
trial should be extended; the HTA agreed and provided
funding for a further period of follow-up.
In this Journal of Vascular Surgery supplement, the
BASIL trial investigators and participants present the final
analysis of the BASIL trial in terms of:
● clinical outcomes: AFS and OS by intention-to-treat and by
treatment received (these analyses are presented separately
because the authors believe it is very important not to conflate
the analysis of randomized and nonrandomized data, please
see below);
● health-related quality of life (HRQOL); and
● cost-effective use of hospital resources.
We also present:
● an analysis of preintervention angiograms so that readers can
appreciate the extent and severity of the disease being treated
in BASIL; and
● a Weibull survival model that examines baseline factors predict-
ing survival of BASIL patients to 2 years, which appears to be the
point in time where the relative merits of BSX and BAP change.
FINAL (2008) INTENTION-TO-TREAT
ANALYSIS
For the final analysis, apart from four patients lost to
follow-up, 100% of the patients had been monitored for 3
years and 54% for5 years, and the longest follow-upwas 7.7
years; 250 patients (56%) were dead, 168 (38%) were alive
without amputation; and 30 (7%)were alive with amputation.
Considering the follow-up period as awhole, AFS andOS
did not differ between randomized treatments. For those
patients who survived 2 years, however, randomization to
BSX was associated with a significant increase in OS of about
7 months and a trend toward increased AFS of about 6
months during the subsequent mean follow-up of about 3
years.
FINAL (2008) BY-TREATMENT-RECEIVED
ANALYSIS
The investigators had not originally intended to under-
take a by-treatment-received analysis of the trial because the
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inevitable. However, surgical and interventional colleagues
urged us to reconsider, and we recognize that, provided it is
interpreted with caution, such an analysis will provide some
useful additional insights. However, the analysis is presented
in a separate article to avoid conflation of randomized and
nonrandomized data. This is a very important point, and so
the senior editor asked that we add a little more explanation.
The intention-to-treat analysis compares patients ran-
domized to a best endovascular (in most cases BAP alone)
first or a best surgery (in most cases BSX) first revascular-
ization strategy. This means that any differences in out-
comes observed between the two groups are overwhelm-
ingly likely to be due to true differences in the clinical and
cost-effectiveness of the two strategies. This is why it is
standard practice to analyze RCTs by intention-to-treat.
By contrast, if one chooses to study outcomes by which
treatment was actually received, then the data inevitably
reflect selection bias on the part of the surgeons and inter-
ventionalists or indeed the patients (and their families).
Similarly, we did not randomize between vein and pros-
thetic BSX, or between transluminal and subintimal BAP.
So by-treatment-received comparisons of outcomes offer a
much lower level of evidence than do intention-to-treat
analyses of randomized data; hence, the evidential weight
given to RCTs over all other forms of study design.
However, bearing those caveats in mind, in the by-
treatment-received analyses, we found that vein performed
significantly better than prosthetic BSX in terms of AFS but
not OS. The data also suggested that most patients would
have been better served by an attempt at BAP rather than
prosthetic BSX if no suitable vein was available as a conduit.
No differences were found between transluminal and sub-
intimal BAP. Patients who underwent BSX after failed BAP
fared significantly worse than those who underwent BSX as
their first treatment. The reasons for this are not clear at the
present time and require further exploration.
ANGIOGRAM SCORING
Preintervention angiograms were assessed using the
Bollinger system by a panel of vascular surgeons and inter-
ventional radiologists unaware of the treatment received or
patient outcomes.8 This was primarily to facilitate appro-
priate generalization of the trial data to other groups of SLI
patients with similar lumenographic burdens of disease. We
chose the Bollinger method over other classifications avail-
able at the inception of the trial because it provides detailed
information on the extent and severity of atherosclerotic
disease by segment.9 In particular, the Bollinger system
allows a very precise description of the infrapopliteal disease
burden, which the investigators believed was likely to have
an important influence on outcome in this patient group.
As was to be expected from the randomization process,
the two arms of the trial were well matched in terms of
disease severity and extent. In patients with the least overall
disease, the disease tended to be concentrated above the
knee; but as the overall burden of disease increased, the
popliteal and crural arteries became increasingly involved.The posterior tibial was the worst affected crural artery,
whereas the peroneal artery appeared relatively spared.
Although the Bollinger scores were generally related to
the TransAtlantic Inter-Society Consensus (TASC) II clas-
sification, cases of significant disagreement also occurred.10
This was mainly because TASC II, unlike the Bollinger
assessment, does not permit the collection of detailed in-
formation for infrapopliteal disease, which BASIL has con-
firmed has a powerful bearing on outcomes after interven-
tion in this group of patients (please see below).
PREDICTING PATIENT OUTCOMES
Because the relative merits of a BSX-first vs a BAP-first
revascularization strategy appear to change at about 2 years
after randomization, a Weibull survival model was devel-
oped to predict the probability of survival to 2 years using
baseline patient and angiographic characteristics. A combi-
nation of age; presence of tissue loss; smoking; a history of
angina, myocardial infarction, stroke, or transient ischemic
attack; serum creatinine; below-knee Bollinger angiogram
score; body mass index; number of recordable ankle pres-
sures; and highest ankle pressure was highly predictive of
survival to more than 2 years after intervention.
HRQOL AND HEALTH ECONOMIC ANALYSIS
HRQOL was nonsignificantly better in the BSX group
before and after randomization. Amputation was associated
with a significant reduction inHRQOL.During the first year,
hospital costs in patients randomized to BSX were signifi-
cantly higher (mean difference, $8469). By the end of 3 years,
the cost differences were no longer significant and this re-
mained the case out to 7 years. Most of the costs related to
ward stays rather than to procedures or the use of high
dependency and intensive care beds. BASIL patients spent an
average of 5 to 6weeks of their first postrandomization year in
the hospital and then 2 to 3 weeks per year thereafter. A
36-month quality-adjusted perspective generates a mean
quality-adjusted lifetime of 442 days for BAP and 452 days for
BSX (not significant) at an estimated additional average hos-
pital cost of $5521. The 3-year cost per QALY point estimate
forBSXcomparedwithBAP is therefore $184,492, indicating
that BSX is unlikely to be cost-effective at conventional UK
willingness to pay thresholds.
IMPLICATIONS FOR PRACTICE
The greatest gains in SLI may lie in early diagnosis,
best medical therapy, and prompt referral. SLI in most
BASIL patients had developed slowly over months, often
years. Despite this, and being at exceptionally high overall
cardiovascular risk, many patients:
● had never received best medical therapy for their multisystem
atherosclerotic disease,
● were referred (too) late to vascular services for (successful)
revascularization, and
● were far from medically optimized at the time of referral.
It seems likely, therefore, that the burden imposed by
SLI in the UK and probably in many other developed and
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measures aimed at:
● detecting lower limb arterial disease at an earlier stage (before
it becomes life and limb threatening),
● ensuring that all such patients are offered evidenced-based
best medical therapy, and
● encouraging prompt referral to vascular services for specialist
care.
Multidisciplinary teamwork. BASIL strongly sug-
gests that the best outcomes for SLI are achieved when
vascular surgeons and interventional radiologists work
closely together with other professionals as part of a
multidisciplinary team in specialized, high-volumes cen-
ters (http://www.vascularsociety.org.uk/).
Treatment recommendations based on BASIL trial
data. In SLI due to infrainguinal disease requiring imme-
diate or early revascularization, patients expected to live:
● 2 years should usually be offered BAP first because they are
unlikely to reap the longer-term benefits of BSX and because
BAP is significantly less expensive and morbid in the short-
term.
● 2 years should usually be offered BSX first; the strength of
this recommendation appears to be greatest where vein is
available as the conduit.
Role of prosthetic BSX in the management of SLI.
Many patients who could not undergo a vein BSX would
probably have been better served by a first attempt at BAP
than by prosthetic BSX. Surgeons should make every effort
to use vein and view prosthetic material as a last resort.
Role of BAP in the management of SLI. The com-
bined immediate technical and early clinical failure rate of
infrainguinal BAP for SLI is high at around 25%. Patients
who underwent BSX after failed BAP fared significantly
worse than those who underwent BSX as their first proce-
dure. So, BAP does not appear to be the “free shot” that it
is often claimed to be. Whether failed BAP selects out
patients who are going to do badly whatever treatment they
receive, or whether a failed BAP per se reduces the chance
of successful surgical revascularization, these data should be
borne in mind when considering treatment strategies.
The role of amputation and the care of vascular
amputees. In retrospect, the interests of a significant pro-
portion of BASIL patients would probably have been better
served by primary amputation, followed by high-quality reha-
bilitation, rather than often repeated and ultimately unsuc-
cessful attempts at revascularization. Amputees tended to
spend long periods on acute surgical wards where they con-
sumed expensive acute resources while not often receiving
the rehabilitation they required. At least in the UK, there
would seem to be a need to rethink the role of amputation
for SLI and the planning of services for vascular amputees
so that the available NHS resources can be used in a more
clinically and cost-effective manner.RESEARCH RECOMMENDATIONS
The investigators suggest that further research is re-
quired in order to:
1. repeat the Delphi studies to determine whether, as a result of
BASIL and other studies, there has been any convergence of
views on the relative merits of BSX and BAP in SLI;
2. confirm or refute the BASIL findings and recommendations in
further RCTs;
3. validate the BASIL trial survival prediction model in a separate
cohort of SLI patients;
4. examine the clinical results and cost-effectiveness of new endo-
vascular techniques and devices in the management of SLI;
5. compare, within the confines of an RCT, (endovascular) revascular-
ization vs primary amputation vs best medical/nursing care only in
those SLI patients with the poorest overall survival prospects; and
6. model the longer-term cost-effectiveness of BSX and BAP and the
possible gains and losses associatedwith an allocationmechanism that
assigns initial treatment on the basis of expected survival.
We respectfully suggest that it is not in the public interest
that responsibility for such research should be left entirelywith
the private sector, where the direction of travel is understand-
ably driven by commercial interests. The case for further
publicly funded trials in this important and challenging area of
vascular and endovascular surgery would seem clear.
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